Physician profile
Sathappan Kumar
NPI 1265589055
$11,566.39
in general payments reported to CMS, 2019-2025
22 companies · $2,612 in 2025
The $2,612 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,193 · 2020: $544 · 2021: $1,605 · 2022: $1,241 · 2023: $816 · 2024: $2,556 · 2025: $2,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Travel and Lodging: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.97 |
| Travel and Lodging | $2,580.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,378.54 | 2019-2025 | Mitris Resilia Mitral Valve |
| Atricure, INC. | $4,237.15 | 2019-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atricure Cryoice Cryosphere Cryoablation System |
| Abiomed | $898.12 | 2021-2025 | Impella |
| Abbott Laboratories | $659.93 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $429.57 | 2021-2025 | Sternalock Blu System, Ribfix Titan |
| Chiesi USA, INC. | $263.07 | 2021-2025 | Cleviprex, Kengreal |
| Medtronic, INC. | $171.97 | 2024 | Ligasure |
| Conmed Corporation | $106.30 | 2025 | Airseal |
| Amgen INC. | $74.68 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $74.15 | 2019 | |
| Terumo Medical Corporation | $44.17 | 2021 | |
| Ethicon US, LLC | $40.50 | 2019-2024 | Harmonic, Echelon Flex, Linx Reflux Management System |
| Alnylam Pharmaceuticals INC. | $28.51 | 2023 | Amvuttra |
| Elutia, INC. | $27.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.88 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.90 | 2025 | Farxiga |
| Idorsia Pharmaceuticals US INC | $15.88 | 2025 | Tryvio |
| Merck Sharp & Dohme LLC | $14.93 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $13.08 | 2022 | |
| Monaghan Medical Corporation | $13.00 | 2022 | |
| Teleflex LLC | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathappan Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.